The present disclosure relates to implantable prosthetic devices. More specifically, the disclosure is directed to an improved prosthetic device implantable by catheter for the treatment of mitral or tricuspid regurgitation.
Mitral Regurgitation is a valvular dysfunction that causes blood volume to flow during systole (during left ventricular contraction) from the left ventricle to the left atrium. In contrast, in a healthy heart, this direction of flow is blocked by the mitral valve. The reverse flow during systole causes pressure to rise in the left atrium, and maintaining a normal cardiac output results in an increased pressure in the left ventricle.
Treating patients with MR (mitral regurgitation) or TR (tricuspid regurgitation) could require valve replacement in order to reduce or eliminate the regurgitation. For many years, the commonly accepted treatment was surgical repair or replacement of the native valve during open heart surgery. In recent years, a trans-vascular technique has been developed for introducing and implanting a prosthetic heart valve using a flexible catheter in a manner that is less invasive than open heart surgery.
In the trans-vascular technique, a prosthetic valve is delivered to the target site (e.g., aortic valve, mitral valve, tricuspid valve, or other valve) through a catheter while the valve is crimped to a low diameter shaft. The valve is then expanded/deployed to a functional size when it is located in the correct position. Examples of such prosthetic valves, and related processes for delivering the valves through a catheter, are described in U.S. Pat. No. 8,518,107, the content of which is hereby incorporated by reference in its entirety.
Advancing the catheter to the target site can be achieved through: (a) The vascular system where a catheter is advanced from the femoral vein/artery, or any other blood vessel that allows access to the target site; (b) Trans-apically where a catheter is advanced through a small incision made in the chest wall and then through the apex; or (c) Trans-atrially where a catheter is advanced through a small incision made in the chest wall and then through the left or right atrium.
Embodiments herein are directed to various prosthetic valve ring assemblies for use in repairing cardiac valves suffering from, for example, mitral or tricuspid regurgitation.
A prosthetic valve ring assembly is described herein. In certain embodiments, the prosthetic valve ring assembly can include an outer tube that includes a plurality of windows; and a plurality of anchors positioned inside the outer tube and about a perimeter of the outer tube. The plurality of anchors are configured to be emitted from the plurality of windows to anchor the prosthetic valve ring assembly to annulus tissue of a patient. In some embodiments, the anchors are configured to be emitted in different directions. For example, a first portion of the anchors are configured to be emitted to a ventricular side of the annulus tissue of the patient and a second portion of the anchors are configured to be emitted to an atrial side of the annulus tissue of the patient.
In some embodiments, the anchors are created using a laser cutting technique. In an embodiment, the laser cutting technique includes cutting according to a laser cut pattern to define a plurality of windows through which the plurality of anchors are configured to be emitted.
In some embodiments, the prosthetic valve ring assembly further includes a closure device configured to lock a distal side and a proximal side of the prosthetic valve ring assembly. In some embodiments, the prosthetic valve ring assembly further includes a post adjustment mechanism that includes a flexible connection configured to move an anterior portion of the prosthetic valve ring assembly relative to a posterior portion of the prosthetic valve ring assembly, thereby changing at least one of a size and a geometry of the prosthetic valve ring assembly.
In some embodiments, the prosthetic valve ring assembly further includes a closure device configured to lock a distal side and a proximal side of the prosthetic valve ring assembly; and an unlocking mechanism configured to unlock the closure device, thereby enabling repositioning or retrieval of the prosthetic valve ring assembly from a patient through a catheter. In some embodiments, the prosthetic valve ring assembly further includes one or more bumps positioned on a perimeter of the prosthetic valve ring assembly and configured to apply additional pressure to trigones of the annulus tissue of the patient, thereby providing improved anchoring of the prosthetic valve ring assembly.
Aspects, features, benefits and advantages of the embodiments described herein will be apparent with regard to the following description, appended claims, and accompanying drawings where:
This disclosure is not limited to the particular systems, devices and methods described, as these may vary. The terminology used in the description is for the purpose of describing the particular versions or embodiments only, and is not intended to limit the scope.
As used in this document, the singular forms “a,” “an,” and “the” include plural references unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art. Nothing in this disclosure is to be construed as an admission that the embodiments described in this disclosure are not entitled to antedate such disclosure by virtue of prior invention. As used in this document, the term “comprising” means “including, but not limited to.”
When implanting a replacement valve (e.g., an aortic valve, mitral valve, tricuspid valve, or other valve), the replacement valve can include a prosthesis attachment. The prosthesis can be configured to secure the replacement valve in a patient's heart. An example of such a prosthesis is the AMEND™ Mitral Valve Repair Annuloplasty ring developed by Valcare Medical. The AMEND™ ring is a D-shaped ring configured to emulate the total valve replacement for patients who suffer from Mitral Regurgitation (MR, as described above). Additional detail related to prosthetic valves for mitral or tricuspid valve replacement can be found in U.S. patent application Ser. No. 14/891,189 entitled “Transcatheter Prosthetic Valve for Mitral or Tricuspid Valve Replacement,” filed May 22, 2013, the content of which is incorporated herein by reference in its entirety.
As described herein, a prosthetic ring can be configured to include various anchor zones on a posterior side. The anchor zones are positioned to emit anchors in different directions and/or angles from two or more windows on the cross section of the ring. For example, a portion of the anchors may be emitted to the ventricular side of the annulus tissue, and a portion of the anchors may be emitted to the atrial side of the annulus tissue. Such an arrangement can provide for improved anchoring of the ring into the annulus tissue as compared to conventional mitral valve rings.
It should be noted that, while the following detailed description of the figures is directed to a prosthetic ring configured to anchor a replacement valve such as the AMEND™ ring as described above, the techniques, ideas, and processes described herein can be applied to any mitral valve ring.
Each anchor zone (including both posterior zone anchors 110 and anterior zone anchors 120) can include atrial side anchors 111 as well as ventricular side anchors 112 (not shown in
As further shown in
The ring assembly 100 can further include a set of pins 103. The pins 103 can be positioned and configured to connect the outer tube 102 to the closure device 150. In certain implementations, the pins 103 can be further positioned and configured to provide for routing of sutures as well as to function as a pulley while providing for rotation of a suture (e.g., 90 degree rotation) with minimal friction.
Additionally, in certain embodiments, various anchors can be configured such that portions of the anchors can cross one another in different directions, thereby creating a closed loop and stapling effect of the tissue. For example, anchors 121 and 122 as shown in
The raw materials of the ring assembly 100 and various components included therein can be selected from various materials, such as various polymers, shape memory materials such as Nitinol, metals such as stainless steel, or other similar materials safe for implanting; into or adjacent to living tissue. In certain implementations, the ring assembly 100 can include a combination of two or more different materials, such as stainless steel 316/316L and Nitinol. This combination is provided by way of example only, and other materials can be used alternately or additionally.
In order to create the ring assembly 100 as described above, the outer tube 102 can be manufactured such that multiple windows are defined. The windows can be positioned to facilitate deployment of the various anchors as described above.
In an alternate embodiment, more than one anchor can be emitted from one window with one or more anchors in the atrial side and one or more anchors in ventricular side. In another embodiment, one or more anchors can be emitted from different windows in the same direction. For example, two windows (e.g., 204A and 204B) can be configured to provide for simultaneous deployment of anchors towards the ventricular side.
To achieve such a configuration, cut pattern 300 as shown in
In certain implementations, the anchor stop feature 308 can be a passive feature that is activated as a result of a force exerted on the anchor zone 302 (e.g., a pulling force) causing a bending or other change to the geometry of the anchor stop feature 308. In other embodiments, the anchor stop feature 308 can include an associated activation mechanism that facilitates activation of the anchor stop feature. For example, the activation mechanism can be an activation pulley that prevents the anchor stop feature 308 from bending of otherwise deforming such that a portion of the anchor stop feature exits through a corresponding hole on the outer tube of the ring assembly. Such an arrangement can lock the anchor zone 302 into position as the anchor stop feature 308 prevents any relative movement. In some examples, pulling on the activator mechanism and removing it from the designated location allows the anchor stop feature 308 to bend and allows relative movement of the anchor zone 302 in relation to the outer tube of the ring assembly.
In certain implementations, the anchor stop feature 308 can be located in either the ventricular side or atrial side of the anchor zone 320 and/or outer tube. Additionally, in various embodiments, the anchor stop feature 308 can be positioned in any location along the anchor zone 302. The position as shown in
It should be noted that laser cutting the ring assemblies as described herein is provided by way of example only, and additional manufacturing techniques can be used. For example, a stamping process can be used to stamp the cut patterns as described above.
In addition, the anchor zone can have a 3D shape that fits the zone location in the final ring assembly. For example, the posterior anchor zones can be curved to fit the posterior curvature of the ring assembly, and the anterior anchor zones can be curved to fit the anterior curvature of the ring assembly.
It should be noted that heat-treated bending and curving is provided by way of example only. Depending upon the type of material being used and the design of the individual components such as the anchor zones, alternative bending and curving techniques can be used to form the anchor zones to the geometry of the final ring assembly.
The female component 402 can further include an unsnapping pin 406. The unsnapping pin can be positioned and configured to unsnap or otherwise disconnect the female component 402 from the cup 404 of the ring assembly. Additionally, the female component 402 can include a pivot pin 408 for attaching the female component to an outer tube of the ring assembly. Additionally, the pivot pin 408 can be configured to function as an interface between the ring assembly and a delivery system, similar to pins 103 as described above.
In certain implementations, the disk 410 and the unsnapping pin 406 can be made from a shape memory alloy such as Nitinol. In some example, the other components of the female component can be made from various metallic materials such as stainless steel, aluminum, Nitinol, and titanium.
As noted above, the cup 404 and the female component 402 are attached together with the unsnapping pin 406. If properly inserted and positioned, the unsnapping pin 406 can visually verify that the two parts are well-attached and cannot open unintentionally. Conversely, upon activation of the unsnapping pin 406 by pulling it in a specific direction, it allows separation of the two components. By doing this, the ring close structure is compromised and the closed shape becomes open and allows retrieval of the implant into the delivery system.
In some embodiments, the female component 402 can have one or more gold markers 412 that provide for confirmation of locking of the cup 404 and the female component during a clinical procedure.
In certain implementations, a ring assembly can further include bumps or other similar protrusions in the trigones area of the ring assembly. For example, as shown in
In certain implementations, additional anchors can be beneficial for providing additional anchoring points for a ring assembly. In some examples, a single anchor or set of additional anchors can be emitted from an existing window in an outer tube of a ring assembly providing a more robust anchoring point as compared to the curved anchors as described above. For example, as shown in
In some implementations, resizing the ring assembly can be desirable as a single ring assembly can accommodate an additional range of patients and valve sizes. For example, a ring assembly can include a flexible connection that is laser cut from a similar material as the outer tube of the ring assembly. The flexible connection can be configured to contract and/or expand to allow for changing the size of the ring before, during, and/or after implantation of the ring assembly. In some examples, the ring assembly can be manufactured from separate segments or components that are configured to be attached together with a mechanism or device that controls expansion and/or contraction of each side of a ring assembly separately or simultaneously.
It should be noted that a ratcheting feature is provided by way of example only. Additional adjustment mechanisms such as friction-based holding devices, snap-based devices, winding devices, and other similar adjustment devices can be used. Additionally, it should be noted that two adjustable components 806 and 808 are shown by way of example. In additional implementations, various numbers of adjustable components can be used. For example, a single adjustable component can be included on one side of the ring assembly.
In some implementations, the anterior portion 812 can be connected to the posterior portion 815 with a first adjustable component 816. Similarly, the anterior portion can be connected to the posterior portion 814 with a second adjustable component 818. The posterior portions 814 and 815 can be configured to releasably attach to one another via a closure device such as closure device 150 as described above.
The ring assemblies as described above can be designed and shaped for various functions such as mitral valve replacement. However, a similar ring assembly can be designed and constructed for tricuspid valve replacement as well. However, a tricuspid ring can be designed with additional features such as a release zone positioned on the ring assembly at a location that will be adjacent to a patient's atrioventricular node or valves.
In certain implementations, the release zone 904 does not have any anchors. Rather, the alternate shape and profile of the release zone provides for interference between the ring assembly 900 and the patient's atrioventricular node or valves, thereby securing the ring assembly in position.
In the above detailed description, reference is made to the accompanying drawings, which form a part hereof. In the drawings, similar symbols typically identify similar components, unless context dictates otherwise. The illustrative embodiments described in the detailed description, drawings, and claims are not meant to be limiting. Other embodiments may be used, and other changes may be made, without departing from the spirit or scope of the subject matter presented herein. It will be readily understood that the aspects of the present disclosure, as generally described herein, and illustrated in the Figures, can be arranged, substituted, combined, separated, and designed in a wide variety of different configurations, all of which are explicitly contemplated herein.
The present disclosure is not to be limited in terms of the particular embodiments described in this application, which are intended as illustrations of various aspects. Many modifications and variations can be made without departing from its spirit and scope, as will be apparent to those skilled in the art. Functionally equivalent methods and apparatuses within the scope of the disclosure, in addition to those enumerated herein, will be apparent to those skilled in the art from the foregoing descriptions. Such modifications and variations are intended to fall within the scope of the appended claims. The present disclosure is to be limited only by the terms of the appended claims, along with the full scope of equivalents to which such claims are entitled. It is to be understood that this disclosure is not limited to particular methods, reagents, compounds, compositions or biological systems, which can, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.
With respect to the use of substantially any plural and/or singular terms herein, those having skill in the art can translate from the plural to the singular and/or from the singular to the plural as is appropriate to the context and/or application. The various singular/plural permutations may be expressly set forth herein for sake of clarity.
It will be understood by those within the art that, in general, terms used herein, and especially in the appended claims (for example, bodies of the appended claims) are generally intended as “open” terms (for example, the term “including” should be interpreted as “including but not limited to,” the term “having” should be interpreted as “having at least,” the term “includes” should be interpreted as “includes but is not limited to,” et cetera). While various compositions, methods, and devices are described in terms of “comprising” various components or steps (interpreted as meaning “including, but not limited to”), the compositions, methods, and devices can also “consist essentially of” or “consist of” the various components and steps, and such terminology should be interpreted as defining essentially closed-member groups. It will be further understood by those within the art that if a specific number of an introduced claim recitation is intended, such an intent will be explicitly recited in the claim, and in the absence of such recitation no such intent is present.
For example, as an aid to understanding, the following appended claims may contain usage of the introductory phrases “at least one” and “one or more” to introduce claim recitations. However, the use of such phrases should not be construed to imply that the introduction of a claim recitation by the indefinite articles “a” or “an” limits any particular claim containing such introduced claim recitation to embodiments containing only one such recitation, even when the same claim includes the introductory phrases “one or more” or “at least one” and indefinite articles such as “a” or “an” (for example, “a” and/or “an” should be interpreted to mean “at least one” or “one or more”); the same holds true for the use of definite articles used to introduce claim recitations.
In addition, even if a specific number of an introduced claim recitation is explicitly recited, those skilled in the art will recognize that such recitation should be interpreted to mean at least the recited number (for example, the bare recitation of “two recitations,” without other modifiers, means at least two recitations, or two or more recitations). Furthermore, in those instances where a convention analogous to “at least one of A, B, and C, et cetera” is used, in general such a construction is intended in the sense one having skill in the art would understand the convention (for example, “a system having at least one of A, B, and C” would include but not be limited to systems that have A alone, B alone, C alone, A and B together, A and C together, B and C together, and/or A, B, and C together, et cetera). In those instances where a convention analogous to “at least one of A, B, or C, et cetera” is used, in general such a construction is intended in the sense one having skill in the art would understand the convention (for example, “a system having at least one of A, B, or C” would include but not be limited to systems that have A alone, B alone, C alone, A and B together, A and C together, B and C together, and/or A, B, and C together, et cetera). It will be further understood by those within the art that virtually any disjunctive word and/or phrase presenting two or more alternative terms, whether in the description, claims, or drawings, should be understood to contemplate the possibilities of including one of the terms, either of the terms, or both terms. For example, the phrase “A or B” will be understood to include the possibilities of “A” or “B” or “A and B.”
In addition, where features or aspects of the disclosure are described in terms of Markush groups, those skilled in the art will recognize that the disclosure is also thereby described in terms of any individual member or subgroup of members of the Markush group.
As will be understood by one skilled in the art, for any and all purposes, such as in terms of providing a written description, all ranges disclosed herein also encompass any and all possible subranges and combinations of subranges thereof. Any listed range can be easily recognized as sufficiently describing and enabling the same range being broken down into at least equal halves, thirds, quarters, fifths, tenths, et cetera. As a non-limiting example, each range discussed herein can be readily broken down into a lower third, middle third and upper third, et cetera. As will also be understood by one skilled in the art all language such as “up to,” “at least,” and the like include the number recited and refer to ranges that can be subsequently broken down into subranges as discussed above. Finally, as will be understood by one skilled in the art, a range includes each individual member. Thus, for example, a group having 1-3 cells refers to groups having 1, 2, or 3 cells. Similarly, a group having 1-5 cells refers to groups having 1, 2, 3, 4, or 5 cells, and so forth.
Various of the above-disclosed and other features and functions, or alternatives thereof, may be combined into many other different systems or applications. Various presently unforeseen or unanticipated alternatives, modifications, variations or improvements therein may be subsequently made by those skilled in the art, each of which is also intended to be encompassed by the disclosed embodiments.
The present application claims benefit of priority under 35 U.S.C. 119(e) to the filing date of U.S. Provisional Patent Application 62/472,633 filed Mar. 17, 2017, entitled, “IMPROVED MITRAL OR TRICUSPID VALVE REPAIR SYSTEM,” the contents of which is incorporated herein by reference in their entirety.
Number | Name | Date | Kind |
---|---|---|---|
4602911 | Ahmadi et al. | Jul 1986 | A |
5236440 | Hlavacek | Aug 1993 | A |
5306296 | Wright et al. | Apr 1994 | A |
5695518 | Laerum | Dec 1997 | A |
5716370 | Williamson, IV et al. | Feb 1998 | A |
5855614 | Stevens et al. | Jan 1999 | A |
6113611 | Allen et al. | Sep 2000 | A |
6231602 | Carpentier et al. | May 2001 | B1 |
6619291 | Hlavka et al. | Sep 2003 | B2 |
6629534 | St. Goar et al. | Oct 2003 | B1 |
6669687 | Saadat | Dec 2003 | B1 |
6689048 | Vanden Hoek et al. | Feb 2004 | B2 |
6726704 | Loshakove et al. | Apr 2004 | B1 |
6776784 | Ginn | Aug 2004 | B2 |
6790229 | Berreklouw | Sep 2004 | B1 |
6797002 | Spence et al. | Sep 2004 | B2 |
6805711 | Quijano et al. | Oct 2004 | B2 |
6893459 | Macoviak | May 2005 | B1 |
7101395 | Tremulis et al. | Sep 2006 | B2 |
7114953 | Wagner | Oct 2006 | B1 |
7175660 | Cartledge et al. | Feb 2007 | B2 |
7238191 | Bachmann | Jul 2007 | B2 |
7285087 | Moaddeb et al. | Oct 2007 | B2 |
7297150 | Cartledge et al. | Nov 2007 | B2 |
7569072 | Berg et al. | Aug 2009 | B2 |
7594887 | Moaddeb et al. | Sep 2009 | B2 |
7635329 | Goldfarb et al. | Dec 2009 | B2 |
7655040 | Douk et al. | Feb 2010 | B2 |
7717954 | Solem et al. | May 2010 | B2 |
7722668 | Moaddeb et al. | May 2010 | B2 |
7758637 | Starksen et al. | Jul 2010 | B2 |
7837729 | Gordon et al. | Nov 2010 | B2 |
7988725 | Gross et al. | Aug 2011 | B2 |
8163014 | Lane et al. | Apr 2012 | B2 |
8182529 | Gordon et al. | May 2012 | B2 |
8236049 | Rowe et al. | Aug 2012 | B2 |
8287591 | Keidar et al. | Oct 2012 | B2 |
8518107 | Tsukashima et al. | Aug 2013 | B2 |
8579968 | Shannon et al. | Nov 2013 | B1 |
9180008 | Yellin | Nov 2015 | B2 |
20020151961 | Lashinski | Oct 2002 | A1 |
20020151970 | Garrison et al. | Oct 2002 | A1 |
20020188170 | Santamore et al. | Dec 2002 | A1 |
20020198526 | Shaolian et al. | Dec 2002 | A1 |
20030050693 | Quijano et al. | Mar 2003 | A1 |
20030078465 | Pai et al. | Apr 2003 | A1 |
20030078671 | Lesniak et al. | Apr 2003 | A1 |
20030191528 | Quijano et al. | Oct 2003 | A1 |
20030198605 | Montgomery | Oct 2003 | A1 |
20030199974 | Lee et al. | Oct 2003 | A1 |
20040044364 | DeVries et al. | Mar 2004 | A1 |
20040068276 | Golden et al. | Apr 2004 | A1 |
20040122514 | Fogarty et al. | Jun 2004 | A1 |
20040138744 | Lashinski et al. | Jul 2004 | A1 |
20040148021 | Cartledge et al. | Jul 2004 | A1 |
20040193191 | Starksen et al. | Sep 2004 | A1 |
20040243230 | Navia et al. | Dec 2004 | A1 |
20040249391 | Cummins | Dec 2004 | A1 |
20040260393 | Rahdert et al. | Dec 2004 | A1 |
20040260394 | Douk et al. | Dec 2004 | A1 |
20050020696 | Montgomery et al. | Jan 2005 | A1 |
20050033325 | May et al. | Feb 2005 | A1 |
20050065550 | Starksen et al. | Mar 2005 | A1 |
20050090846 | Pedersen et al. | Apr 2005 | A1 |
20050096740 | Langberg et al. | May 2005 | A1 |
20050113910 | Paniagua et al. | May 2005 | A1 |
20050137692 | Haug et al. | Jun 2005 | A1 |
20050137695 | Salahieh et al. | Jun 2005 | A1 |
20050203549 | Realyvasquez | Sep 2005 | A1 |
20050222678 | Lashinski et al. | Oct 2005 | A1 |
20050240200 | Bergheim | Oct 2005 | A1 |
20050267572 | Schoon et al. | Dec 2005 | A1 |
20050283190 | Huitema et al. | Dec 2005 | A1 |
20050288778 | Shaoulian et al. | Dec 2005 | A1 |
20050288781 | Moaddeb et al. | Dec 2005 | A1 |
20060009737 | Whiting et al. | Jan 2006 | A1 |
20060020327 | Lashinski | Jan 2006 | A1 |
20060122633 | To | Jun 2006 | A1 |
20060129025 | Levine et al. | Jun 2006 | A1 |
20060155165 | Vanden Hoek et al. | Jul 2006 | A1 |
20060161169 | Nieminen et al. | Jul 2006 | A1 |
20060184240 | Jimenez et al. | Aug 2006 | A1 |
20060184242 | Lichtenstein | Aug 2006 | A1 |
20060195134 | Crittenden | Aug 2006 | A1 |
20060195183 | Navia et al. | Aug 2006 | A1 |
20060241748 | Lee et al. | Oct 2006 | A1 |
20060282161 | Huynh et al. | Dec 2006 | A1 |
20070016287 | Cartledge et al. | Jan 2007 | A1 |
20070027533 | Douk | Feb 2007 | A1 |
20070038296 | Navia et al. | Feb 2007 | A1 |
20070051377 | Douk et al. | Mar 2007 | A1 |
20070067027 | Moaddeb et al. | Mar 2007 | A1 |
20070073098 | Lenker et al. | Mar 2007 | A1 |
20070080188 | Spence et al. | Apr 2007 | A1 |
20070093854 | Kayan | Apr 2007 | A1 |
20070118215 | Moaddeb | May 2007 | A1 |
20070128132 | Piergallini et al. | Jun 2007 | A1 |
20070135913 | Moaddeb et al. | Jun 2007 | A1 |
20070142907 | Moaddeb et al. | Jun 2007 | A1 |
20070213812 | Webler et al. | Sep 2007 | A1 |
20070233239 | Navia et al. | Oct 2007 | A1 |
20070239272 | Navia et al. | Oct 2007 | A1 |
20070244553 | Rafiee et al. | Oct 2007 | A1 |
20070244554 | Rafiee et al. | Oct 2007 | A1 |
20070244555 | Rafiee et al. | Oct 2007 | A1 |
20070244556 | Rafiee et al. | Oct 2007 | A1 |
20070250161 | Dolan | Oct 2007 | A1 |
20070293942 | Mirzaee | Dec 2007 | A1 |
20080177380 | Starksen et al. | Jul 2008 | A1 |
20080177381 | Navia et al. | Jul 2008 | A1 |
20080200980 | Robin et al. | Aug 2008 | A1 |
20080243220 | Barker | Oct 2008 | A1 |
20080262513 | Stabler et al. | Oct 2008 | A1 |
20080262609 | Gross et al. | Oct 2008 | A1 |
20080306586 | Cartledge et al. | Dec 2008 | A1 |
20090088838 | Shaolian et al. | Apr 2009 | A1 |
20090118747 | Bettuchi et al. | May 2009 | A1 |
20090125098 | Chuter | May 2009 | A1 |
20090149872 | Gross et al. | Jun 2009 | A1 |
20090216322 | Le et al. | Aug 2009 | A1 |
20090222083 | Nguyen et al. | Sep 2009 | A1 |
20090238778 | Mordas et al. | Sep 2009 | A1 |
20090299470 | Rao et al. | Dec 2009 | A1 |
20100010616 | Drews et al. | Jan 2010 | A1 |
20100030014 | Ferrazzi | Feb 2010 | A1 |
20100063586 | Hasenkam et al. | Mar 2010 | A1 |
20100121433 | Bolling et al. | May 2010 | A1 |
20100161047 | Cabiri | Jun 2010 | A1 |
20100185274 | Moaddeb et al. | Jul 2010 | A1 |
20100211166 | Miller et al. | Aug 2010 | A1 |
20100249920 | Bolling et al. | Sep 2010 | A1 |
20100266989 | Piergallini et al. | Oct 2010 | A1 |
20100280605 | Hammer et al. | Nov 2010 | A1 |
20100286767 | Zipory et al. | Nov 2010 | A1 |
20110022168 | Cartledge | Jan 2011 | A1 |
20110027753 | Maurat et al. | Feb 2011 | A1 |
20110034953 | Milo | Feb 2011 | A1 |
20110066231 | Cartledge et al. | Mar 2011 | A1 |
20110093062 | Cartledge et al. | Apr 2011 | A1 |
20110106245 | Miller et al. | May 2011 | A1 |
20110106247 | Miller et al. | May 2011 | A1 |
20110137397 | Chau et al. | Jun 2011 | A1 |
20110166649 | Gross et al. | Jul 2011 | A1 |
20110190879 | Bobo et al. | Aug 2011 | A1 |
20110208298 | Tuval et al. | Aug 2011 | A1 |
20110224785 | Hacohen | Sep 2011 | A1 |
20110257728 | Kuehn | Oct 2011 | A1 |
20110282361 | Miller et al. | Nov 2011 | A1 |
20110301698 | Miller et al. | Dec 2011 | A1 |
20110301699 | Saadat | Dec 2011 | A1 |
20120022557 | Cabiri et al. | Jan 2012 | A1 |
20120022644 | Reich et al. | Jan 2012 | A1 |
20120059458 | Buchbinder et al. | Apr 2012 | A1 |
20120095455 | Rodmond et al. | Apr 2012 | A1 |
20120123531 | Fsukashima et al. | May 2012 | A1 |
20120136436 | Cabiri et al. | May 2012 | A1 |
20120165930 | Gifford et al. | Jun 2012 | A1 |
20120245604 | Tegzes | Sep 2012 | A1 |
20120310330 | Buchbinder et al. | Dec 2012 | A1 |
20130087598 | Surti | Apr 2013 | A1 |
20130116780 | Miller et al. | May 2013 | A1 |
20130166022 | Conklin | Jun 2013 | A1 |
20130204361 | Adams et al. | Aug 2013 | A1 |
20130226289 | Shaolian et al. | Aug 2013 | A1 |
20130226290 | Yellin et al. | Aug 2013 | A1 |
20130282114 | Schweich, Jr. et al. | Oct 2013 | A1 |
20130289718 | Tsukashima et al. | Oct 2013 | A1 |
20130289720 | Dobrilovic | Oct 2013 | A1 |
20130304197 | Buchbinder et al. | Nov 2013 | A1 |
20140005778 | Buchbinder et al. | Jan 2014 | A1 |
20140046433 | Kovalsky | Feb 2014 | A1 |
20140058505 | Bielefeld | Feb 2014 | A1 |
20140114407 | Rajamannan | Apr 2014 | A1 |
20150173897 | Raanani et al. | Jun 2015 | A1 |
20150351903 | Morriss et al. | Dec 2015 | A1 |
20160022419 | Yellin et al. | Jan 2016 | A1 |
20160038286 | Yellin et al. | Feb 2016 | A1 |
20160089235 | Yellin | Mar 2016 | A1 |
20160106420 | Foerster et al. | Apr 2016 | A1 |
20160120642 | Shaolian et al. | May 2016 | A1 |
20160120645 | Alon | May 2016 | A1 |
20160331534 | Buchbinder et al. | Nov 2016 | A1 |
20170042670 | Shaolian et al. | Feb 2017 | A1 |
20170231763 | Yellin | Aug 2017 | A1 |
20180042723 | Yellin et al. | Feb 2018 | A1 |
20180161160 | Shaolian et al. | Jun 2018 | A1 |
20180161161 | Yellin et al. | Jun 2018 | A1 |
Number | Date | Country |
---|---|---|
102014102653 | Sep 2015 | DE |
2600799 | Jun 2013 | EP |
2967700 | Jan 2016 | EP |
20040095482 | Nov 2004 | KR |
125062 | Feb 2013 | RU |
9009153 | Feb 1990 | WO |
9009153 | Aug 1990 | WO |
03017874 | Mar 2003 | WO |
03047467 | Jun 2003 | WO |
2005046488 | May 2005 | WO |
2009052427 | Apr 2009 | WO |
2009120764 | Oct 2009 | WO |
2010004546 | Jan 2010 | WO |
2010085659 | Jul 2010 | WO |
2011011443 | Jan 2011 | WO |
2011097355 | Aug 2011 | WO |
2012004679 | Jan 2012 | WO |
2012019052 | Feb 2012 | WO |
2012063228 | May 2012 | WO |
2012095159 | Jul 2012 | WO |
2012106354 | Aug 2012 | WO |
2012167095 | Dec 2012 | WO |
2013095816 | Jun 2013 | WO |
2013128436 | Sep 2013 | WO |
2013130641 | Sep 2013 | WO |
2013175468 | Nov 2013 | WO |
2014089424 | Jun 2014 | WO |
2014145399 | Sep 2014 | WO |
2014189509 | Nov 2014 | WO |
2014190329 | Nov 2014 | WO |
2014210600 | Dec 2014 | WO |
2015132668 | Sep 2015 | WO |
2018035118 | Feb 2018 | WO |
2018170424 | Sep 2018 | WO |
Entry |
---|
Communication pursuant to Article 94(3) EPC for EP 14801009.3 dated Sep. 27, 2018. |
European Search Report in EP 17155803.4 dated Aug. 9, 2017. |
International Search Report and Written Opinion for PCT/US2014/044920 dated Dec. 24, 2014. |
International Search Report and Written Opinion for PCT/US2011/046659 dated Jun. 4, 2012. |
International Search Report and Written Opinion for PCT/US2012/040481 dated Dec. 6, 2012. |
International Search Report and Written Opinion for PCT/US2013/042275 dated Feb. 20, 2014. |
International Search Report and Written Opinion for PCT/US2013/073552 dated Mar. 6, 2014. |
International Search Report and Written Opinion for PCT/US2014/039545 dated Oct. 22, 2014. |
International Search Report and Written Opinion for PCT/US2014/030163 dated Aug. 27, 2014. |
International Search Report and Written Opinion for PCT/US2013/058102 dated Apr. 21, 2014. |
International Search Report for PCT/US2013/028065 dated Jun. 27, 2013. |
Lendlein et al. Biodegradable, Elastic Shape-Memory Polymers for Potential Biomedical Applications (May 31, 2002), Science 296:1673-1676. |
Supplemental European Search Report and Written Opinion for EP 12793292.9 dated Dec. 1, 2014. |
Supplemental European Search Report and Written Opinion for EP 14762806.9 dated Jul. 29, 2016. |
Supplementary Partial European Search Report for EP 13755441 dated Nov. 3, 2015. |
International Search Report and Written Opinion for PCT/US17/46933 dated Dec. 21, 2017. |
International Search Report and Written Opinion for PCT2019/064289 dated Feb. 5, 2020. |
International Search Report and Written Opinion for PCT/US2018/022910 dated May 23, 2018. |
13860442.6, Extended European Search Report, dated Aug. 11, 2016, 7 pages. |
19151726.7, Extended European Search Report, dated Jul. 22, 2019, 9 pages. |
PCT/US2014/039454, International Search Report and Written Opinion, dated Oct. 22, 2014, 10 pages. |
PCT/US2019/064289, International Search Report and Written Opinion, dated Feb. 5, 2020. |
Number | Date | Country | |
---|---|---|---|
20190091022 A1 | Mar 2019 | US |
Number | Date | Country | |
---|---|---|---|
62472633 | Mar 2017 | US |